The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025#Norway#Oslo#Bladder_Cancer#Photocure_ASA#BRAVO_Study
The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025
The latest findings from the BRAVO study showcase the cost neutrality of blue light versus white light cystoscopy in treating bladder cancer, emphasizing real-world savings.
third-news.com
December 8, 2025 at 7:37 AM
The BRAVO Study: Cost Neutrality in Cystoscopy for Bladder Cancer Patients Presented at SUO 2025#Norway#Oslo#Bladder_Cancer#Photocure_ASA#BRAVO_Study